<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03518788</url>
  </required_header>
  <id_info>
    <org_study_id>ORBV-CHIR-001</org_study_id>
    <nct_id>NCT03518788</nct_id>
  </id_info>
  <brief_title>Malignant Pleural Effusion: Pleur-X vs. Chemical Pleurodesis in VATS</brief_title>
  <acronym>Pleur-X</acronym>
  <official_title>Randomized Clinical Trial to Evaluate the Efficacy of the Permanent Thoracic Catheter (Pleur-X) Towards Pleurodesis in Thoracoscopy in the Treatment of Malignant Pleural Effusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rolf Inderbitzi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Trial Unit EOC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ente Ospedaliero Cantonale, Bellinzona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective randomized study whose aim is to compare the efficacy of the permanent
      thoracic catheter (Pleur-X) versus chemical pleurodesis in videothoracoscopy (VATS) in the
      treatment of malignant pleural effusion at the first diagnosis.Patients with malignant
      pleural effusion for whom there is indication of surgery and who agree to participate in the
      study will be randomized 1: 1 in the Pleur-X arm (arm 1) or in the chemical pleurodesis arm
      (arm 2).

      The arm 1 provides for the installation of a permanent drainage under local anesthesia while
      the arm 2 provides a pleurodesis with talc in VATS under general anesthesia.

      Both procedures are standard of care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before the study procedure the patients will be requested to perform some examination as
      physical and radiological examination. Patients will also complete questionnaires for quality
      of life assessment (EORTC QLQ 30) and symptoms (VAS for pain). Patients will then be
      randomized into one of the two arms.

      For patients included in arm 1, a permanent drainage (Pleur-X) is provided under local
      anesthesia performed on an outpatient basis while for patients included in arm 2 a
      pleurodesis with talc in VATS is planned under general anesthesia. Arm 2 patients will be
      hospitalized for 5 days.

      Patients will then be followed up to 3 months after surgery. During this period a medical
      examination will be required at 1 week, 4 weeks and 3 months after the intervention during
      which the patient will be asked to complete questionnaires for the evaluation of quality of
      life (EORTC QLQ 30) and symptoms (VAS for pain ). A chest radiograph will be performed after
      four weeks to evaluate the primary parameter. Adverse events will be collected throughout the
      study period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success rate of the treatment with VPM</measure>
    <time_frame>4 weeks</time_frame>
    <description>Evaluate the success rate of the treatment with VPM with radiological examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluate the tollerability of both procedures collecting adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of live</measure>
    <time_frame>3 months</time_frame>
    <description>quality of live will be determined with the evaluation of the EORTC QLQ 30 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scale</measure>
    <time_frame>3 months</time_frame>
    <description>Pain will be evaluated with the Visual Analogue Scale (VAS) where the score of 0 is no pain while the score 10 is very painfull</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">234</enrollment>
  <condition>Malignant Pleural Effusion</condition>
  <arm_group>
    <arm_group_label>Pleur-X</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placement of a permanent drainage under local anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pleurodesis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pleurodesis with talc in VATS</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pleur-X</intervention_name>
    <description>Permanent drainage</description>
    <arm_group_label>Pleur-X</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pleurodesis</intervention_name>
    <description>Pleurodesis with talc in permanent VATS</description>
    <arm_group_label>pleurodesis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 18 years, &lt;80 years

          -  First diagnosis of malignant pleural effusion

          -  Indication to treat the malignant pleural effusion with surgery

          -  Informed informed consent

        Exclusion Criteria:

          -  Previous surgeries on the same hemitorace

          -  Pregnant women

          -  Trapped lung syndrome

          -  Patients with estimated life expectancy &lt; 4-8 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rolf Inderbitzi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ente Ospedaliero Cantonale, Bellinzona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rolf Inderbitzi, MD</last_name>
    <phone>+41 (0)91 811 91 76</phone>
    <email>rolf.inderbitzi@eoc.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefano Cafarotti, MD</last_name>
    <phone>+41 (0)91 811 93 40</phone>
    <email>stefano.cafarotti@eoc.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale San Giovanni</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rolf Inderbitzi, MD</last_name>
      <phone>+41 (0)91 811 91 76</phone>
      <email>rolf.inderbitzi@eoc.ch</email>
    </contact>
    <contact_backup>
      <last_name>Stefano Cafarotti, MD</last_name>
      <phone>+41 (0)91 811 93 40</phone>
      <email>stefano.cafarotti@eoc.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2018</study_first_submitted>
  <study_first_submitted_qc>April 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2018</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ente Ospedaliero Cantonale, Bellinzona</investigator_affiliation>
    <investigator_full_name>Rolf Inderbitzi</investigator_full_name>
    <investigator_title>Head of thoracic surgery department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pleural Effusion</mesh_term>
    <mesh_term>Pleural Effusion, Malignant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

